Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)
a study on Lymphoma
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at Irvine, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- by Daniela Bota
Description
Summary
This study will evaluate the efficacy, safety, and pharmacokinetics of tirabrutinib in patients with relapsed or refractory PCNSL
Official Title
An Open-label Phase II Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Tirabrutinib in Patients With Primary Central Nervous System Lymphoma (PCNSL)
Keywords
Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL) Bruton's Tyrosine Kinase (BTK) Inhibitor, tirabrutinib, ONO-4059, PROSPECT, relapsed, refractory, first line Lymphoma Tirabrutinib Tirabrutinib monotherapy
Eligibility
You can join if…
Open to people ages 18 years and up
- Written informed consent by the patient prior to screening
- Patients aged ≥ 18 years on the day of consenting to the study
- Pathologic diagnosis of PCNSL
- Relapse or refractory PCNSL with at least one prior HD MTX based therapy for PCNSL
- Measurable brain lesion with a minimum diameter > 1.0 cm in gadolinium enhanced magnetic resonance imaging (MRI) performed within 14 days before starting tirabrutinib treatment
- ECOG PS of 0, 1 or 2
- Life expectancy of at least 3 months
- Adequate bone marrow, renal, and hepatic function
You CAN'T join if...
- Intraocular PCNSL with no brain lesion
- Patient who is intolerant of contrast enhanced MRI due to allergic reactions to contrast agents
- Patient with non-B cell PCNSL
- Patient with systemic presence of lymphoma
- Prior chemotherapy within 21 days, nitrosourea within 42 days, an antibody drug with anticancer activity (e.g., rituximab) within 28 days, prior radiotherapy within 14 days, prior major invasive surgery within 28 days, or allogeneic stem cell transplant within 6 months before starting tirabrutinib treatment
- Prior BTK inhibitor treatment
- Prior investigational drugs (including treatment in clinical research, unapproved combination products, and new dosage forms) within 28 days or 5 half-lives, whichever is shorter, before starting tirabrutinib treatment
- Concomitant systemic corticosteroid on an ongoing basis within 14 days before starting tirabrutinib treatment, with the exception of the following:
- Equivalent of up to 10 mg/day of prednisone for a disease other than PCNSL
- Equivalent of up to 50 mg/day of prednisone (equal to 8 mg/day of dexamethasone) for patients with lesions of the brain or spinal cord or both
- Patient who has received a CYP3A4 inducer or P-gp inducer within 14 days before starting tirabrutinib treatment
- . Concomitant warfarin, any other warfarin derivative anticoagulant, vitamin K antagonists, novel oral anticoagulants, or antiplatelet therapy on an ongoing basis within 7 days before starting tirabrutinib treatment
- . Active malignancy, other than PCNSL requiring systemic therapy
- . Poorly controlled comorbidity, severe heart, severe lung disease, clinically significant liver diseases that could affect protocol compliance or safety or efficacy assessments
- . Patient with bleeding diathesis
- . Patients with a history of moderate or severe hepatic impairment
- . QTcF > 480 milliseconds or requirement for ongoing treatment with concomitant medications that prolong the QT interval
- . Active infection, including a HIV, cytomegalovirus infection or SARS-CoV-2, or has had, within 28 days before starting tirabrutinib treatment, an infection (other than nail trichophytosis) that requires hospitalization or an intravenous antibiotic
- . Prior history of hypersensitivity or anaphylaxis to tirabrutinib
- . Prior history of Stevens Johnson Syndrome or Toxic Epidermal Necrolysis
- . Medical history of organ allografts
- . Tests positive for HIV-1 antibody and HIV-2 antibody, human T-lymphotropic virus 1 antibody, HBs antigen, or HCV antibody. Tests positive for HBs antibody or hepatitis B virus core protein antibody and has a result of at least detectable in a hepatitis B virus deoxyribonucleic acid assay despite testing negative for HBs antigen.
- . Patient is unable to swallow tablets; has malabsorption, malabsorption syndrome, or a comorbidity that affects gastric function; has undergone complete resection of the stomach or small intestine; has ulcerative colitis or symptomatic inflammatory bowel disease; or has partial or complete intestinal obstruction.
- . Women who are pregnant or lactating
- . Patient is found incapable of giving consent due to dementia or another such condition
- . Patient is found to be otherwise ineligible for the study by the Investigator or sub-Investigator.
Locations
- University of California, Irvine
accepting new patients
Irvine California 92868 United States - City of Hope Comprehensive Breast Cancer Center
not yet accepting patients
Duarte California 91010 United States
Lead Scientist at UC Irvine
- Daniela Bota
Professor, Neurology. Authored (or co-authored) 78 research publications
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Ono Pharmaceutical Co. Ltd
- Links
- Related Info
- ID
- NCT04947319
- Phase
- Phase 2 research study
- Study Type
- Interventional
- Participants
- Hope to have 44 study participants
- Last Updated
Please contact me about this study
We will not share your information with anyone other than the team in charge of this study. Submitting your contact information does not obligate you to participate in research.
Thank you!
The study team should get back to you in a few business days.